{"search_session":{},"preferences":{"l":"ar","queryLanguage":"ar"},"patentId":"064-114-242-638-507","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"064-114-242-638-507","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11664,"type":"PATENT","title":"University of Muenster - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":977,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8328,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately:uni* muenster; uni* Münster
Select more for logical variants.
Add to collection.
Select all patents in the collection and expand by simple families.
Add to collection. Total patents: 863
Search Applicants and Owners separately:uni* muenster; uni* Münster
Select more for logical variants.
Add to collection.
Select all patents in the collection and expand by simple families.
Add to collection. Total patents: 863
(a) obtaining a biological sample, wherein the biological sample is from a human individual, and the biological sample comprises nucleic acid;\n
(b) detecting point mutations (substitutions) (i)-(iv) in the individual's ANXA5 gene regulation element as follows:\n\n(i) a G to A substitution at a position which corresponds to position 186 of SEQ ID NO: 2,\n(ii) an A to C substitution at a position which corresponds to position 203 of SEQ ID NO: 2,\n(iii) a T to C substitution at a position which corresponds to position 229 of SEQ ID NO: 2, and\n(iv) a G to A substitution at a position which corresponds to position 276 of SEQ ID NO: 2; and\n
(c) diagnosing the individual with, or detecting in the individual, a predisposition for a tendency to pregnancy loss (waste) and/or a higher risk to develop anti-phospholipid antibodies."],"number":1,"annotation":false,"claim":true,"title":false},{"lines":["An in vitro method for diagnosing or detecting a predisposition for a tendency to pregnancy loss (waste) and/or a higher risk to develop anti-phospholipid antibodies in a human, said method comprising steps of\n
(1) obtaining a biological sample, wherein the biological sample is from a human individual, and the biological sample comprises nucleic acid;\n
(2) haplotyping the individual with an M2 haplotype, and optionally\n
N or M1 haplotypes, comprising a substep of\n\n(a) detecting in the sample that there is a G to A substitution at position 186, an A to C substitution at position 203, a T to C substitution at position 229, and a G to A substitution at position 276 of the individual's copy of the ANXA5 gene regulation element by comparison to SEQ ID NO: 2, for which the individual is assigned haplotype M2; and\n(b) optionally detecting in the sample that there is an A to C substitution at position 203, and a T to C substitution at position 229 of the individual's copy of the ANXA5 gene regulation element by comparison to SEQ ID NO: 2, for which the individual is assigned haplotype M1; or\n(c) optionally detecting in the sample that there are no point mutations at positions 186, 203, 229, and 276 of the individual's copy of the ANXA5 gene regulation element by comparison to SEO ID NO: 2, for which the individual is assigned haplotype N;\n
(3) assigning said individual genotype M2/N, M2/M2 or M1/M2; and\n
(4) diagnosing the individual with, or detecting in the individual, a predisposition for a tendency to pregnancy loss (waste) and/or a higher risk to develop anti-phospholipid antibodies in a human."],"number":2,"annotation":false,"claim":true,"title":false},{"lines":["The in vitro method of claim 1, whereby the detection of said point mutations (substitutions) in said ANXA5 gene regulation element is carried out or determined by a nucleic acid technique based on size or sequence."],"number":3,"annotation":false,"claim":true,"title":false},{"lines":["The in vitro method of claim 3, whereby said nucleic acid technique based on size or sequence is selected from the group consisting of hybridization techniques, nucleic acid sequencing, PCR (polymerase chain reaction), restriction fragment determination, single nucleotide polymorphism (SNPs)-determination, LCR (ligation chain reaction) or restriction fragment length polymorphism (RFLP)-determination."],"number":4,"annotation":false,"claim":true,"title":false},{"lines":["The in vitro method of claim 4, whereby said restriction fragment determination or said RFLP comprises the determination of the absence (BAMHI−) or the presence (BAMHI+) of a BAMHI restriction site, whereby said BAMHI restriction site is the restriction site corresponding to nucleotide 276 to nucleotide 281 of SEQ ID NO: 2."],"number":5,"annotation":false,"claim":true,"title":false},{"lines":["The in vitro method of claim 5, whereby the absence of said BAMHI restriction site (BAMHI−) is indicative of a predisposition for pregnancy loss."],"number":6,"annotation":false,"claim":true,"title":false},{"lines":["The in vitro method of claim 1, whereby said detection of said point mutations (substitutions) comprises the use of suitable PCR (polymerase chain reaction) primers."],"number":7,"annotation":false,"claim":true,"title":false},{"lines":["The in vitro method according to claim 1, wherein said\n
detecting point mutations (substitutions) (i)-(iv) in a human individual's ANXA5 gene regulation element comprises\n
use of suitable PCR (polymerase chain reaction) primers selected from the group consisting of:\n
(i) a forward primer as defined in SEQ ID NO: 8 or 9 and a reverse primer as defined in SEQ ID NO: 10 or 13 for detection of the G to A substitution at position 186 of SEQ ID NO: 2;\n
(ii) a forward primer as defined in SEQ ID NO: 11 or 12 and a reverse primer as defined in SEQ ID NO: 13 or 10 for detection of the A to C substitution at position 203 of SEQ ID NO: 2;\n
(iii) a forward primer as defined in SEQ ID NO: 14 or 15 and a reverse primer as defined in SEQ ID NO: 16 or 7 for detection of the T to C substitution at position 229 of SEQ ID NO: 2; and\n
(iv) a forward primer as defined in SEQ ID NO: 5 or 6 and a reverse primer as defined in SEQ ID NO: 7 or 16 for detection of the G to A substitution at position 276 of SEQ ID NO: 2."],"number":8,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 2, whereby said haplotyping comprises the use of primers as shown in SEQ ID NOS: 5 to 16."],"number":9,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 2, which is carried out on genomic DNA."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 10, wherein said genomic DNA is isolated from the biological sample."],"number":11,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 2, whereby said biological sample is selected from the group consisting of blood, serum, urine, amniotic fluid, vaginal secretions and sputum."],"number":12,"annotation":false,"claim":true,"title":false},{"lines":["The in vitro method of claim 2, whereby the detection of said at least one point mutation (substitution) in said ANXA5 gene regulation element is carried out or determined by a nucleic acid technique based on size or sequence."],"number":13,"annotation":false,"claim":true,"title":false},{"lines":["The in vitro method of claim 13, whereby said nucleic acid technique based on size or sequence is selected from the group consisting of hybridization techniques, nucleic acid sequencing, PCR (polymerase chain reaction), restriction fragment determination, single nucleotide polymorphism (SNPs)-determination, LCR (ligation chain reaction) or restriction fragment length polymorphism (RFLP)-determination."],"number":14,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, which is carried out on genomic DNA."],"number":15,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 15, wherein said genomic DNA is isolated from the biological sample."],"number":16,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, whereby said biological sample is selected from the group consisting of blood, serum, urine, amniotic fluid, vaginal secretions and sputum."],"number":17,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}